‘The Global Lyophilisation Market Will be Worth $3.25bn by 2015′ Says Visiongain Consultancy Firm
By Visiongain, PRNEMonday, June 27, 2011
LONDON, June 28, 2011 -
-
www.visiongain.com/Report/633/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021
A new report by visiongain, a London-based business information
provider, predicts that the global lyophilisation market will be
worth $3.25bn by 2015. The market generated $1.99bn in 2010,
according to Lyophilisation for Pharmaceuticals: Technology and
Services Market 2011-2021, published in June 2011.
Lyophilisation, also known as freeze drying, is a
well-established technique used in the pharmaceutical industry, as
well as in other industries. In the pharmaceutical industry
lyophilisation helps to stabilise labile/unstable products such as
vaccines and biologics (biological drugs). This market has
significant potential for growth with developments in freeze drying
technology that will benefit the industry and its customers,
extending performance and applications.
Visiongain’s market industry analyst, says: “The market for
lyophilisation has enjoyed strong growth in recent years, driven by
new products and drug classes, especially in biotechnology. Over
the course of the decade there will be greater demand for
lyophilisation services, particularly those driven by the growing
market for injectable therapeutics.”
Visiongain’s research suggests that the world lyophilisation
market will benefit from the launch of new biologic drugs and
vaccines. For biologic drugs, parenteral routes of administration
will remain the most important. Lyophilisation is an established
method in the formulation of biological products. There are
under-met needs for improved stability and cost effectiveness, as
well as for more convenience in transport, storage and use of
therapeutic agents. Rapid stabilisation, long-term product
stability, ease of reconstitution and process advantages for
heat-sensitive products will drive growth of the lyophilisation
technology and services market.
Visiongain predicts that this market will grow steadily to 2021.
The future of the lyophilisation industry and market appears
promising, with increasing demand in many therapeutic areas. This
new study complements visiongain’s wide range of analytical reports
in healthcare and other industry areas.
For further information about this study please click on:
www.visiongain.com/Report/633/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021
Or contact Sara Peerun
Email:
Tel: +44(0)207-336-6100
Web:
Table of Contents
1. Executive Summary
1.1 Lyophilisation Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction to Lyophilisation (Freeze Drying)
2.1 Introduction
2.1.1 What is Freeze Drying?
2.1.2 Why Freeze Dry?
2.1.3 A Brief History
2.2 General Description of the Process
2.2.1Freezing
2.2.2 Primary Drying (Sublimation)
2.2.3 Secondary Drying (Desorption)
2.3 Freeze Drying Equipment
2.3.1 Components of the Freeze Dryer
2.3.1.1 Drying Chamber
2.3.1.2 Condenser
2.3.1.3 Vacuum Pump
2.3.1.4 Refrigeration System
2.3.1.5 Control Facilities
2.4 Type of Freeze Dryers
2.4.1Rotary Freeze Dryers
2.4.2 Manifold Freeze Dryers
2.4.3 Tray Freeze Dryers
2.5 Applications of Lyophilisation
2.5.1 Pharmaceutical and Biotechnology Industry
2.5.2 Other Chemical and Technological Sectors
2.5.3 Veterinary Applications
2.5.4 Food Industry Applications
2.5.5 What Products Are Freeze Dried?
2.5.6 How do Freeze Dryers for Food Differ from those for
Pharmaceutical Applications?
2.5.7 Other Applications for Lyophilisation
3. Lyophilisation Technology and Services Market, 2010-2021
3.1 Scope and Limitations
3.2 The World Lyophilisation Technology and Services Market in
2010
3.2.1 Marketed Lyophilised Drugs, 2010
3.2.2 Total Lyophilisation Market was Worth $1.99bn in 2010
3.3 Sales Forecast for Overall Lyophilisation Market,
2010-2015
3.4 Sales Forecast for Overall Lyophilisation Market,
2016-2021
3.5 Breakdown of the Global Lyophilisation Market
3.5.1 Sales Forecast for cGMP Lyophilisers, 2011-2021
3.5.2 Sales Forecast for Laboratory Lyophilisers, 2011-2021
3.5.3 Sales Forecast for Lyophilisation Services, 2011-2021
3.6 Leading National Markets for Lyophilisation Technology and
Services, 2010
3.6.1 Leading National Markets for Lyophilisation Technology and
Services: Sales Forecast, 2011-2021
3.6.2 The US Lyophilisation Technology and Services Market,
2011-2021
3.6.3 The Japanese Lyophilisation Technology and Services Market,
2011-2021
3.6.4 The Leading European Lyophilisation Technology and Services
Markets, 2011-2021
3.6.5 Emerging Economy Lyophilisation Technology and Services
Markets
3.6.6 The Chinese Lyophilisation Technology and Services Market,
2011-2021
3.6.7 The Indian Lyophilisation Technology and Services Market,
2011-2021
4. Worldwide Market for Lyophilised Products and Technology
4.1 Therapeutic Areas Offering Growth Opportunities
4.2 Development of Biologics and Vaccines Will Drive the
Lyophilisation Market, 2011-2021
4.3 The Leading Sectors of Biological Drugs Market in 2010
4.3.1 Monoclonal Antibodies Currently Lead the Biotech Market
4.3.1.1 Long-Term Prospects for Monoclonal Antibodies and
Implications for the Lyophilisation Market
4.3.2 The Human Insulins Class Will Exhibit Strong Growth
4.3.3 Erythropoietin Products - How Will Reported Safety Affect
Sales?
4.3.3.1 Erythropoietin Products Forecast, 2011-2021
4.3.4 The Interferons Class will Show an Increase in Revenues from
2010-2015
4.3.4.1 Long-Term Forecast for the Interferons Class
4.3.5 Granular-Colony Stimulating Factors (G-CSF), 2011-2021
4.3.6 Recombinant Coagulation Factors Will Show Steady Growth
4.3.7 Other Therapeutic Proteins
4.3.8 Biosimilars Market, 2010
4.3.8.1 Forecast for the Biosimilars Market, 2011-2021
4.3.9 Vaccines Market, 2010-2021
5. Systems, Consumables and Service Providers in the Lyophilisation
Industry and Market
5.1 Products and Services in the Lyophilisation Market
5.1.1 Equipment Providers
5.1.2 Consumables Providers
5.1.3 Contract Manufacturing Organisations (CMOs) Providing
Lyophilisation Services
5.2 Profiles of Some Leading Companies
5.2.1 GEA Lyophil
5.2.1.1 Overview
5.2.1.2 Capabilities of GEA Lyophil
5.2.1.3 GEA Lyophil’s Research and Development Freeze Dryers
5.2.1.4 GEA Lyophil’s Pilot Freeze Dryers
5.2.1.5 GEA’s Lyovac Production Lyophilisers
5.2.1.6 Lyophilisation Production Systems
5.2.1.7 GEA’s Retrofits of Lyophilisers
5.2.1.8 GEA’s VAPOVAC: Technology for Freeze Dryer
Sterilisation
5.2.1.9 ALUS: GEA Lyophil’s Automatic Loading and Unloading Systems
for Lyophilisers
5.2.1.10 GEA’s Thermodynamic Lyophilisation Control
5.2.1.11 GEA Lyophil’s Fast Track Project Management
5.2.2 Labconco Corporation
5.2.2.1 Overview
5.2.2.2 Global Presence
5.2.2.3 Product Focus
5.2.2.4 Dry Ice Benchtop Freeze Dry System
5.2.2.5 FreeZone Benchtop Freeze Dry Systems
5.2.2.6 FreeZone Console Freeze Dry Systems
5.2.2.7 FreeZone Plus Cascade Freeze Dry Systems
5.2.2.8 FreeZone Triad Freeze Dry Systems
5.2.2.9 Labconco Freeze Dry Accessories
5.2.2.10 R&D
5.2.2.11 Future Outlook
5.2.3 Vetter Pharma-Fertigung
5.2.3.1 An Overview
5.2.3.2 Global Presence
5.2.3.3 Business Interests
5.2.3.3.1 Vetter Development Service
5.2.3.3.2 Vetter Commercial Manufacturing
5.2.3.3.3 Vetter Solutions
5.2.3.4 Capabilities
5.2.3.5 R&D
5.2.3.6 Product Focus
5.2.3.6.1 Dual-Chamber Technology
5.2.3.7 Future Outlook
5.2.4 Piramal Pharma Solutions
5.2.4.1 Overview
5.2.4.2 Global Presence
5.2.4.3 Strengths and Capabilities
6. SWOT Analysis of the Lyophilisation Technology Market
6.1 Introduction
6.2 Commercial Drivers of the Lyophilisation Technology
Market
6.3 Commercial Restraints for the Lyophilisation Technology
Market
6.3.1 High Entry Barriers to Sector
6.3.2 Product Formulation Challenges
6.3.3 R&D Stage for Lyophilised Products
6.3.4 Scale-up Stage for Lyophilised Products
6.3.5 Main Issues at Large Scale Production Stage for Lyophilised
Products
6.3.6 Main Challenges in a Freeze Drying Plant
6.3.7 Main Issues in Production
6.3.8 Typical Deficiencies in a Freeze Drying Process
6.4 Challenges Facing the Lyophilisation Technology Industry and
Market
6.4.1 Spray Drying of Biopharmaceuticals
6.4.2 Other Methods in Development
6.4.2.1 Roche’s Precipitation Method
7. Opinion from Our Survey of the Industry
7.1 Interview with Ms Jennifer Thompson, VP Corporate Development
& Investor Relations, EnWave Corporation and Ms Florian Loesch,
Sales Manager, Optima Pharma Group
7.1.1 Market for Lyophilised Products and Outsourcing of
Lyophilisation Work
7.1.2 On the Key Unmet Needs and Driving Forces
7.1.3 Novel Dehydration Technologies in Development by EnWave
Corporation
7.1.4 Development Status of bioREV and freezeREV Technology
7.1.5 On the Advantages Offered by bioREV and freezeREV
7.2 Authority from a Company in the Sector (Views Provided
Anonymously)
7.2.1 Market for Lyophilised Products
7.2.2 Outsourcing of Lyophilisation Work
7.2.3 On the Key Unmet Needs and Driving Forces
7.2.4 On the Capability and Capacity of the CMO
7.3 Interview with Dr Steven Nail, Baxter Healthcare Corporation,
USA
7.3.1 Market Valuation for Freeze Drying?
7.3.2 Products Suitable for Lyophilisation
7.3.3 Percentage of Lyophilised Products on Market
7.3.4 Key Areas for Research and Development
7.3.5 On Advantages of Lyophilisation
7.3.6 On Advantages of Lyophilisation over Other Drug Delivery
Systems
7.3.7 On Drawbacks of Lyophilisation over Other Technologies
7.3.8 On Novel Technologies and Developments
8. Conclusions
8.1 Overview
8.2 Prominent Companies in the Market
8.3 Commercial Drivers of the Lyophilisation Market
8.4 Future Outlook and Concluding Remarks
Notes for Editors
About visiongain
Visiongain is one of the fastest growing and most innovative
independent media companies in Europe. Based in London, UK,
visiongain produces a host of business-2-business conferences,
newsletters, management reports and e-zines focusing on the
Pharmaceutical, Telecoms, Energy, Defence and Materials
sectors.
Visiongain publishes reports produced by its in-house analysts, who
are qualified experts in their field. Visiongain has firmly
established itself as the first port-of-call for the business
professional, who needs independent, high quality, original
material to rely and depend on.
If you are interested in a more detailed overview of this
report, please send an e-mail to
or call her on +44(0)207-336-6100
.
Tags: June 28, London, United Kingdom, Visiongain
